The city of Columbia, Missouri, currently has 6 active clinical trials seeking participants for Diabetes research studies.
Growth Hormone Resistance of Beta-cells
Recruiting
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/16/2025
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Gestational Diabetes, Obesity, Healthy
Lipoprotein Kinetics in T1D
Recruiting
The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
10/25/2024
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Type 1 Diabetes
Impact GLP-1 Agonists Following Bariatric
Recruiting
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: University of Missouri Hospital, Columbia, Missouri
Conditions: Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Recruiting
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: * screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/22/2024
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Recruiting
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: * screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/22/2024
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: University of Missouri-Columbia, Columbia, Missouri
Conditions: Type2Diabetes, ASCVD